Sanofi plans to buy back $152M in Genzyme CVRs

Sanofi ($SNY) plans to buy back up to $152 million in contingent value rights linked to last year's buyout of Genzyme. The French drugmaker says it would purchase about 30% of the CVRs, which pay off if certain Genzyme sales targets are met. The move is seen as a sign that Sanofi is confident that the multiple sclerosis drug Lemtrada will be as lucrative as hoped. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.